EP300 and cancer: Studies in normal and cancer cells suggest a model in which p300 recruits BRD4 to hyperacetylated enhancers and super-enhancers and in turn, BRD4 augmented p300’s HAT activity, a positive feed-forward mechanism that enriches hyperacetylation of enhancers and super-enhancers52–54.